By Fineline Cube 
Denmark-based dermatology specialist LEO Pharma A/S announced that the Greater Bay Area’s first prescription of its first‑in‑class topical pan‑JAK inhibitor, Anzupgo (Delgocitinib cream), was written at the Zhongshan Chenxinghai Integrated Traditional Chinese and Western Medicine Hospital. The approval, granted under the Greater Bay Area Access Policy for Drugs and Medical Devices in July 2025, marks the drug’s official entry into mainland Greater Bay Area medical institutions.
What Is Anzupgo?
- Targeted Therapy: Anzupgo is the first topical medication specifically designed for adults with moderate‑to‑severe chronic hand eczema (CHE) who have not responded adequately to, or are unsuitable for, corticosteroid therapy.
- Mechanism of Action: The cream inhibits all members of the Janus kinase (JAK) family—JAK1, JAK2, JAK3, and TYK2—thereby blocking the JAK‑STAT signaling cascade that drives CHE pathogenesis.
Regulatory and Market Context
- Greater Bay Area Access: The drug’s approval follows the region’s expedited access policy, which aims to accelerate the availability of innovative therapies across Guangdong, Hong Kong, and Macao.
- Clinical Impact: By offering a steroid‑free option, Anzupgo addresses a significant unmet need among patients who experience steroid‑related adverse events or have contraindications to systemic or topical steroids.
Strategic Implications for Leo Pharma
- Regional Lead: Securing the first prescription in the Greater Bay Area positions Leo Pharma as a front‑runner in dermatological innovation within the high‑growth Chinese market.
- Pipeline Momentum: The success of Anzupgo may accelerate the company’s broader portfolio of JAK‑targeted therapies and strengthen its competitive stance against other biologics and small‑molecule agents in dermatology.-Fineline Info & Tech